Brief: Zyversa Therapeutics And Larkspur Health Acquisition Corp. Announce Business Combination, Interim Financing And Pipe Investment Update
27/09/2022 18:05
Sept 27 (Reuters) - Larkspur Health Acquisition Corp LSPR.O :
* ZYVERSA THERAPEUTICS AND LARKSPUR HEALTH ACQUISITION CORP. ANNOUNCE
BUSINESS
COMBINATION, INTERIM FINANCING AND PIPE INVESTMENT UPDATE
* LARKSPUR HEALTH ACQUISITION CORP - COMBINED COMPANY EXPECTED TO BE NAMED
ZYVERSA
THERAPEUTICS, INC. AND LISTED ON NASDAQ UNDER TICKER "ZVSA"
* LARKSPUR HEALTH ACQUISITION CORP - AGGREGATE COMMITTED FINANCING IN
SUPPORT OF
BUSINESS COMBINATION NOW AT $10.0 MILLION
* LARKSPUR HEALTH ACQUISITION CORP - PIPE INVESTMENT IS ANTICIPATED TO CLOSE
WITH
CLOSING OF TRANSACTION, WHICH IS EXPECTED TO TAKE PLACE IN Q4 OF 2022
Source text for Eikon: ID:nPnbwfT1Ma
Further company coverage: LSPR.O
((reuters.briefs@thomsonreuters.com))
Recent news on Zyversa Therapeutics
See all newsBrief: ZyVersa Therapeutics Announces Share Purchase Agreement for up to $10 Million
Brief: ZyVersa Unveils Potential Of Inflammasome Inhibitors In Combination With GLP-1 Agonists To Address Needs Of People Living With Obesity
Brief: Zyversa Therapeutics Announces Published Data Showing Inflammasome Asc Inhibitor IC 100 Decreases Microglial Inflammasome Activation
Brief: ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative Research And Development Trends For Inflammasome Inhibitors, And Provides Update On Inflammasome ASC Inhibitor IC 100’S Development Status
Brief: Zyversa Therapeutics Files For Prospectus Related To Offer & Resale Of Up To 1.6 Million Shares Of Common Stock By Selling Stockholder - SEC Filing